NVIDIA To $200? Here Are 10 Top Analyst Forecasts For Monday
Analysts raised targets for HAS, NCMI, BNTC, KR, COST, IBP and CRWD; cut targets for DVN, SPCE and NVDA. NCMI upgraded to Buy.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Analysts raised targets for HAS, NCMI, BNTC, KR, COST, IBP and CRWD; cut targets for DVN, SPCE and NVDA. NCMI upgraded to Buy.
Wedbush Securities has increased its price target for Benitec Biopharma Inc. from $17 to $20 while maintaining an 'Outperform' rating.
Benitec Biopharma announced its financial results for the fiscal quarter ended September 30, 2026, and reported positive interim clinical data for its BB-301 program.
Filed: 2026-11-13 AccNo: 0001193125-26-459339 Size: 378 KB Item 2.02: Results of Operations and Financial Condition Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Benitec Biopharma reported positive interim results from its Phase 1b/2a study of BB-301, showing robust and durable improvements in swallowing function for patients with Oculopharyngeal Muscular Dystrophy (OPMD).
Raymond James has initiated coverage on Benitec Biopharma Inc. with an "Outperform" rating and a price target of $14.00 per share.